文献速递胸部肿瘤

完全切除且证实纵隔N2受累的非小细胞肺癌患者术后放疗对比无术后放疗(Lung ART):开放标签随机3期试验

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-12-15

Lung ART 是一项开放标签、随机、3 期优效性试验,比较纵隔术后放疗(PORT)与不放疗在完全切除、经细胞学或组织学证实 N2 受累的非小细胞肺癌(NSCLC)患者中的效果。2007年8月7日至2018年7月17日入组501例,随机分为 PORT 组252例和对照组249例;3年无病生存率 PORT 组47%(95%CI 40-54)vs 对照组44%(95%CI 37-51),HR 0.86(95%CI 0.68-1.08;p=0.18)。作者结论为适形 PORT 不能推荐作为 IIIAN2 期 NSCLC 的标准治疗。

要点

  • 3年无病生存率 PORT 组47% vs 对照组44%,HR 0.86(95%CI 0.68-1.08;p=0.18)。
  • 3-4级肺炎 PORT 组13例(5%)vs 对照组1例(<1%);晚期3-4级心肺毒性 PORT 组26例(11%)vs 对照组12例(5%)。
  • 作者结论:适形 PORT 不能推荐作为 IIIAN2 期 NSCLC 患者的标准治疗。

核心结论

  • 在完全切除且证实纵隔 N2 受累的 NSCLC 患者中,PORT 组3年无病生存率47%(95%CI 40-54)vs 对照组44%(95%CI 37-51),HR 0.86(95%CI 0.68-1.08;p=0.18),PORT 未较无 PORT 提高无病生存。
  • 作者结论为适形 PORT 不能推荐作为 IIIAN2 期 NSCLC 患者的标准治疗。

研究设计与样本

  • Lung ART 为开放标签、随机、3 期优效性试验,比较纵隔 PORT 与无 PORT,纳入完全切除、行淋巴结探查且细胞学或组织学证实 N2 受累的 NSCLC 患者。
  • 患者年龄18岁及以上、WHO 体能状态0-2,来自5个国家(法国、英国、德国、瑞士、比利时)的64家医院和癌症中心,按1:1随机分组,最小化因素包括机构、化疗、受累纵隔淋巴结站数、组织学及治疗前 PET 扫描。
  • PORT 剂量为54 Gy,分27或30次,每周连续5天;强制使用三维适形放疗,有经验的中心允许调强放疗。
  • 主要终点为意向治疗分析的无病生存率(3年);PORT 组未接受放疗者及对照组无随访者被排除在安全性分析之外。
  • 2007年8月7日至2018年7月17日入组501例,PORT 组252例、对照组249例;截至2019年5月31日,中位随访4.8年(IQR 2.9-7.0)。

主要发现

  • 3年无病生存率 PORT 组47%(95%CI 40-54)vs 对照组44%(95%CI 37-51);中位无病生存 PORT 组30.5个月(95%CI 24-49)vs 对照组22.8个月(95%CI 17-37),HR 0.86(95%CI 0.68-1.08;p=0.18)。
  • 最常见3-4级不良事件:肺炎 PORT 组13/241例(5%)vs 对照组1/246例(<1%);淋巴细胞减少 PORT 组9例(4%)vs 对照组0例;乏力 PORT 组6例(3%)vs 对照组1例(<1%)。
  • 晚期3-4级心肺毒性 PORT 组26例(11%)vs 对照组12例(5%)。
  • PORT 组有2例死于肺炎(部分与放疗和感染相关),1例死于化疗毒性(脓毒症)且判定为治疗相关;均在 PORT 组。

临床怎么用

  • 作者结论为适形 PORT 不能推荐作为 IIIAN2 期 NSCLC 患者的标准治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with non-small-cell lung cancer (NSCLC), the use of postoperative radiotherapy (PORT) has been controversial since 1998, because of one meta-analysis showing a deleterious effect on survival in patients with pN0 and pN1, but with an unclear effect in patients with pN2 NSCLC. Because many changes have occurred in the management of patients with NSCLC, the role of three-dimensional (3D) conformal PORT warrants further investigation in patients with stage IIIAN2 NSCLC. The aim of this study was to establish whether PORT should be part of their standard treatment. METHODS: Lung ART is an open-label, randomised, phase 3, superiority trial comparing mediastinal PORT to no PORT in patients with NSCLC with complete resection, nodal exploration, and cytologically or histologically proven N2 involvement. Previous neoadjuvant or adjuvant chemotherapy was allowed. Patients aged 18 years or older, with an WHO performance status of 0-2, were recruited from 64 hospitals and cancer centres in five countries (France, UK, Germany, Switzerland, and Belgium). Patients were randomly assigned (1:1) to either the PORT or no PORT (control) groups via a web randomisation system, and minimisation factors were the institution, administration of chemotherapy, number of mediastinal lymph node stations involved, histology, and use of pre-treatment PET scan. Patients received PORT at a dose of 54 Gy in 27 or 30 daily fractions, on five consecutive days a week. Three dimensional conformal radiotherapy was mandatory, and intensity-modulated radiotherapy was permitted in centres with expertise. The primary endpoint was disease-free survival, analysed by intention to treat at 3 years; patients from the PORT group who did not receive radiotherapy and patients from the control group with no follow-up were excluded from the safety analyses. This trial is now closed. This trial is registered with ClinicalTrials.gov number, NCT00410683. FINDINGS: Between Aug 7, 2007, and July 17, 2018, 501 patients, predominantly staged with 18F-fluorodeoxyglucose (18F-FDG) PET (456 [91%]; 232 (92%) in the PORT group and 224 (90%) in the control group), were enrolled and randomly assigned to receive PORT (252 patients) or no PORT (249 patients). At the cutoff date of May 31, 2019, median follow-up was 4·8 years (IQR 2·9-7·0). 3-year disease-free survival was 47% (95% CI 40-54) with PORT versus 44% (37-51) without PORT, and the median disease-free survival was 30·5 months (95% CI 24-49) in the PORT group and 22·8 months (17-37) in the control group (hazard ratio 0·86; 95% CI 0·68-1·08; p=0·18). The most common grade 3-4 adverse events were pneumonitis (13 [5%] of 241 patients in the PORT group vs one [<1%] of 246 in the control group), lymphopenia (nine [4%] vs 0), and fatigue (six [3%] vs one [<1%]). Late-grade 3-4 cardiopulmonary toxicity was reported in 26 patients (11%) in the PORT group versus 12 (5%) in the control group. Two patients died from pneumonitis, partly related to radiotherapy and infection, and one patient died due to chemotherapy toxicity (sepsis) that was deemed to be treatment-related, all of whom were in the PORT group. INTERPRETATION: Lung ART evaluated 3D conformal PORT after complete resection in patients who predominantly had been staged using (18F-FDG PET-CT and received neoadjuvant or adjuvant chemotherapy. 3-year disease-free survival was higher than expected in both groups, but PORT was not associated with an increased disease-free survival compared with no PORT. Conformal PORT cannot be recommended as the standard of care in patients with stage IIIAN2 NSCLC. FUNDING: French National Cancer Institute, Programme Hospitalier de Recherche Clinique from the French Health Ministry, Gustave Roussy, Cancer Research UK, Swiss State Secretary for Education, Research, and Innovation, Swiss Cancer Research Foundation, Swiss Cancer League.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Le Pechoux C, Pourel N, Barlesi F, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021. PMID: 34919827. doi:10.1016/S1470-2045(21)00606-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。